Literature DB >> 10606358

Mortality in rheumatoid arthritis: have we made an impact in 4 decades?

S E Gabriel1, C S Crowson, W M O'Fallon.   

Abstract

OBJECTIVE: To evaluate trends in survival among patients with rheumatoid arthritis (RA) over the past 4 decades.
METHODS: Three population based prevalence cohorts of all Rochester, Minnesota, residents age > or =35 years with RA (1987 American College of Rheumatology criteria) on January 1, 1965, January 1, 1975, and January 1, 1985; and an incidence cohort of all new cases of RA occurring in the same population between January 1, 1955 and January 1, 1985, were followed longitudinally through their entire medical records (including all inpatient and outpatient care by any provider) until death or migration from the county. Mortality was described using the Kaplan-Meier method and the influence of age, sex, rheumatoid factor (RF) positivity, and comorbidity (using the Charlson Comorbidity Index) on mortality was analyzed using Cox proportional hazards models.
RESULTS: Mortality was statistically significantly worse than expected for each of the cohorts (overall p<0.0001). A trend toward increased mortality in the 1975 and 1985 prevalence cohorts compared to the 1965 prevalence cohort was present, even after adjusting for significant predictors of mortality (age, RF positivity, and comorbidity). Survival for the general population of Rochester residents of similar age and sex improved in 1975 compared to 1965, and in 1985 compared to 1975.
CONCLUSION: The excess mortality associated with RA has not changed in 4 decades. Moreover, people with RA have not enjoyed the same improvements in survival experienced by their non-RA peers. More attention should be paid to mortality as an outcome measure in RA.

Entities:  

Mesh:

Year:  1999        PMID: 10606358

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  38 in total

Review 1.  Rheumatoid arthritis in 2003: where are we now with treatment?

Authors:  M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

Review 3.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases.

Authors:  Hilal Maradit Kremers; Elena Myasoedova; Cynthia S Crowson; Guergana Savova; Sherine E Gabriel; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

4.  Does the "Hispanic paradox" occur in rheumatoid arthritis? Survival data from a multiethnic cohort.

Authors:  Emily Molina; Roy Haas; Inmaculada del Rincon; Daniel F Battafarano; Jose F Restrepo; Agustin Escalante
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-07       Impact factor: 4.794

5.  Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role.

Authors:  Liang Hao; Guochun Zhu; Yun Lu; Min Wang; Joel Jules; Xuedong Zhou; Wei Chen
Journal:  FEBS Lett       Date:  2015-04-17       Impact factor: 4.124

6.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

7.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Authors:  C Turesson; W M O'Fallon; C S Crowson; S E Gabriel; E L Matteson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

8.  Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.

Authors:  Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

9.  A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs.

Authors:  L Klareskog; M Gaubitz; V Rodriguez-Valverde; M Malaise; M Dougados; J Wajdula
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.